about
The Janus kinases (Jaks)Multiple angiopoietin recombinant proteins activate the Tie1 receptor tyrosine kinase and promote its interaction with Tie2Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contactsRegulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1.Receptor tyrosine kinase-mediated angiogenesisThe Bmx tyrosine kinase is activated by IL-3 and G-CSF in a PI-3K dependent mannerThe Schlemm's canal is a VEGF-C/VEGFR-3-responsive lymphatic-like vesselAngiopoietin signaling in the vasculatureClaudin-like protein 24 interacts with the VEGFR-2 and VEGFR-3 pathways and regulates lymphatic vessel developmentLiprin (beta)1 is highly expressed in lymphatic vasculature and is important for lymphatic vessel integrity.Regulation of the Jak2 tyrosine kinase by its pseudokinase domainThe pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.The sinus venosus contributes to coronary vasculature through VEGFC-stimulated angiogenesis.Endothelial destabilization by angiopoietin-2 via integrin β1 activation.VEGF-C and aortic cardiomyocytes guide coronary artery stem development.Molecular regulation of lymphangiogenesis.Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation.Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasisAssociation of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.VEGF-C is required for intestinal lymphatic vessel maintenance and lipid absorptionSignaling and functions of angiopoietin-1 in vascular protection.Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapyHow do angiopoietins Tie in with vascular endothelial growth factors?VEGF and angiopoietin signaling in tumor angiogenesis and metastasis.Transcriptomal comparison of human dermal lymphatic endothelial cells ex vivo and in vitro.Binding of SH2-B family members within a potential negative regulatory region maintains JAK2 in an active stateVascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis.Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain.Double target for tumor mass destruction.Simvastatin pretreatment reduces caspase-9 and RIPK1 protein activity in rat cardiac allograft ischemia-reperfusion.Interferon gamma activation of Raf-1 is Jak1-dependent and p21ras-independent.Blocking integrin inactivation as an anti-angiogenic therapy.Platelet-derived growth factor (PDGF)-induced activation of signal transducer and activator of transcription (Stat) 5 is mediated by PDGF beta-receptor and is not dependent on c-src, fyn, jak1 or jak2 kinases.The yin, the yang, and the angiopoietin-1.Ligand oligomerization state controls Tie2 receptor trafficking and angiopoietin-2-specific responses.Loss of endothelial Tie1 receptor impairs lymphatic vessel development-brief report.Donor simvastatin treatment prevents ischemia-reperfusion and acute kidney injury by preserving microvascular barrier function.Angiopoietin-2 inhibition prevents transplant ischemia-reperfusion injury and chronic rejection in rat cardiac allografts.Recessive primary congenital lymphoedema caused by a VEGFR3 mutation.
P50
Q21194856-E3606A2B-7B50-47E5-B97C-2C804EA77FE4Q24300714-61856973-ACD9-4545-A987-4AC0015EC906Q24323888-C6D5E9B8-AD13-43BD-89C7-2BF25C14CF6EQ24537294-6BCA5781-CD74-49BF-93E2-A0E992D9F5F5Q27001612-A1EFB69C-0B9D-426D-AF7E-B3F8A36F1630Q28144756-D17FD204-971B-449E-ACC3-444162BF2261Q28244709-646269FA-A32A-471A-A7E3-E2F8C52B7B18Q28287317-A6E550A7-9D3B-4ACC-B8E9-CB5CB9CF245CQ28586394-A81C6FF0-79FE-4803-8F2F-A11FEA0E826DQ33627007-B7540F9B-F430-4D3A-B09D-9FEF05384550Q34508384-3C15765F-0ED6-408E-A250-59A70636B224Q34527668-D6704993-2990-4777-B4C5-D57058512C7EQ34999372-D0D16BB6-AAA7-4E3B-85BB-2E0243ADE20CQ35047913-F1AB7B28-FDCE-405E-AFD3-2726FA9BAD57Q35140087-31E208A2-A628-4B7B-8D28-35F2CAF45CBAQ35778237-F8366FAD-FE97-40D7-9CE5-4E110771CE7FQ35810919-CBCFBCAA-2D33-45A8-A56E-10DED317BDD1Q35842980-421FD949-E12D-4C81-BEA2-03BEC2F31FA3Q35995721-1E04ADD6-2179-4BFC-83EC-EC0DF1136018Q36278721-C8C90FD9-F402-4499-963F-94F14CAEC985Q36462707-2537B4D3-63B0-4259-A7F9-116F9B4401C3Q37524215-2F288B8F-CF5D-4E7C-B457-E29A9A5FCC84Q37726921-B844517D-39AC-4826-8D5A-20DF1843E826Q37863809-BA69FBED-BA8C-46A1-839B-005AFB6872D7Q38305668-E3834711-EB23-4D6D-8E6B-18A1526F7B76Q38410030-2C8D0044-542F-4224-9DAB-38F0C6599631Q39203228-B7EEBFF5-CB10-45B5-BE51-0630795EDCC8Q39745564-2C36684C-76C3-4BC9-9EFE-0A8586F2AA9AQ39750399-F09035A6-F475-4C67-8D73-9AD8155172FAQ40765140-FD9FA280-D092-426E-81AC-1DF38CE6BD11Q41063440-631C9F2C-BF96-40BA-8816-5B5676B72D9BQ41392672-28156EFD-C4A0-4CD7-8998-59332019C4C3Q41984679-2DD1171A-1D6C-4E30-8FD5-A7FA466028D4Q42181417-E31E5091-C75A-4BDF-897E-9078F6BF2C86Q42799168-52715C02-EF60-4DEE-9941-37B7AD6C810CQ43886365-500DD18E-97E8-4D91-B2D1-ABF165AE7BD7Q46382042-AAE18089-1C52-40C7-ADB4-E1F680DB5656Q51743348-0102F619-3FDD-45A2-8590-F491BBDE0190Q51766990-46D258E9-FFDE-4D8C-9676-784A66C0ED6D
P50
description
Finnish researcher, biochemist ...... essor), University of Helsinki
@en
Fins associate professor
@nl
suomalainen tutkija, biokemist ...... dosentti (Helsingin yliopisto)
@fi
name
Pipsa Saharinen
@ast
Pipsa Saharinen
@ca
Pipsa Saharinen
@en
Pipsa Saharinen
@es
Pipsa Saharinen
@fi
Pipsa Saharinen
@fr
Pipsa Saharinen
@ga
Pipsa Saharinen
@nb
Pipsa Saharinen
@nl
Pipsa Saharinen
@pl
type
label
Pipsa Saharinen
@ast
Pipsa Saharinen
@ca
Pipsa Saharinen
@en
Pipsa Saharinen
@es
Pipsa Saharinen
@fi
Pipsa Saharinen
@fr
Pipsa Saharinen
@ga
Pipsa Saharinen
@nb
Pipsa Saharinen
@nl
Pipsa Saharinen
@pl
altLabel
P Saharinen
@en
P. Saharinen
@en
prefLabel
Pipsa Saharinen
@ast
Pipsa Saharinen
@ca
Pipsa Saharinen
@en
Pipsa Saharinen
@es
Pipsa Saharinen
@fi
Pipsa Saharinen
@fr
Pipsa Saharinen
@ga
Pipsa Saharinen
@nb
Pipsa Saharinen
@nl
Pipsa Saharinen
@pl
P1053
C-9601-2016
P2038
Pipsa_Saharinen
P21
P27
P31
P3829
P496
0000-0003-2652-0584
P569
2000-01-01T00:00:00Z
P6634
pipsa-saharinen-5b675510b